![](/img/cover-not-exists.png)
Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective
Dr Kurt Neeser,Georg Lübben,Uwe Siebert,Wendelin SchrammVolume:
22
Language:
english
Journal:
PharmacoEconomics
DOI:
10.2165/00019053-200422050-00006
Date:
April, 2004
File:
PDF, 174 KB
english, 2004